Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
MAP Kise Interacting Serine/Threonine Protein Kise 1 (MAP Kise Sigl Integrating Kise 1 or MKNK1 or EC 2.7.11.1) - Overview
MAP Kise Interacting Serine/Threonine Protein Kise 1 (MAP Kise Sigl Integrating Kise 1 or MKNK1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
MAP Kise Interacting Serine/Threonine Protein Kise 1 (MAP Kise Sigl Integrating Kise 1 or MKNK1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
MAP Kise Interacting Serine/Threonine Protein Kise 1 (MAP Kise Sigl Integrating Kise 1 or MKNK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AUM Biosciences Pte Ltd
eFFECTOR Therapeutics Inc
Eli Lilly and Co
Oncodesign SA
MAP Kise Interacting Serine/Threonine Protein Kise 1 (MAP Kise Sigl Integrating Kise 1 or MKNK1 or EC 2.7.11.1) - Drug Profiles
AUM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETC-17804452 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKNK1 and MKNK2 for Oncology and Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tomivosertib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAP Kise Interacting Serine/Threonine Protein Kise 1 (MAP Kise Sigl Integrating Kise 1 or MKNK1 or EC 2.7.11.1) - Dormant Products
MAP Kise Interacting Serine/Threonine Protein Kise 1 (MAP Kise Sigl Integrating Kise 1 or MKNK1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Mar 29, 2019: eFFECTOR Therapeutics to present data on Tomivosertib at AACR 2019 annual meeting
Jan 14, 2019: Research published in ture Medicine demonstrates the immunological effects of Tomivosertib, including inhibiting production of checkpoint protein PD-L1 and increasing T Cell Infiltration into tumors
Dec 11, 2018: eFFECTOR initiates dosing in phase 2 trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
Jul 27, 2018: eFFECTOR initiates dosing of eFT508 (tomivosertib) in a phase 2 add-on (CPI-A) trial in combition with checkpoint inhibitors to treat patients with insufficient response to checkpoint inhibitors alone
Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combition Trial of eFT508 and Avelumab in Colorectal Cancer
Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Jourl of Medicil Chemistry
Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting
Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
Dec 05, 2017: Oncodesign Reports Positive Results for Its MNK1/2 Program
Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combition Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017
Apr 10, 2017: Cancer Genetics is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AUM Biosciences Pte Ltd, H2 2019
Pipeline by eFFECTOR Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Oncodesign SA, H2 2019
Dormant Projects, H2 2019